SGLT2-
mediated glucose reabsorption driving excess sodium
reabsorption might cause volume expansion, and SGLT2
inhibitors would be expected to block this eff ect.80 This
blocking eff ect is a potentially powerful mechanism for
protection against heart failure and could be a route
through which an additional component of the
cardiovascular benefi t is achieved. The drug class might
also have benefi cial eff ects on the kidney,13 suggesting
another mechanism by which SGLT2 inhibitors might
protect against vascular disease.